
Chinese pharmaceutical company established on 21 July 2003 in Huichuan district, Zunyi, Guizhou with 53.97 million yuan of registered capital. Runs five controlled subsidiaries and eight GMP-certified production lines for capsules, tablets, granules, wall-broken decoction pieces, patches and plasters, with twelve oral formulation products, five plaster approvals, 54 wall-broken decoction piece approvals and 58 plant health drink approvals. Its core products are Shexiang Huoxue Huayu plaster, Kelintong capsules, Shenbei Guchang capsules and levamlodipine besylate tablets, all added to China's national reimbursement list in 2020. Recognised as a national high-tech enterprise for twelve consecutive years with eleven Chinese invention patents, one global class 1 new drug in development and seven international patents in the United States, Japan and elsewhere.
評価を残す